Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

VJOncology

- PMLiVE

Aduro pancreatic cancer vaccine trial disappoints

Immunotherapy combination fails to improve overall survival over existing treatments

A frugal future

Novartis, GSK and AZ show that the demand for value is shaping our industry

Video: Global Biosimilars Market

Research director of Therapy Watch, Laurent Chanroux, discusses the growth opportunities for biosimilars and the importance of adaptable market tracking for pre and post product launch

Inizio

Case study: Understanding Patient Willingness to Pay in Emerging Markets

Our client wanted to identify the optimum selling price for their chronic disease treatment in emerging markets, based on patient’s willingness to pay for the product out of pocket.Find out...

Inizio

From promise to practice: immuno-oncology in action Part 3 – Emerging Markets

Our latest white paper on immuno-oncology explores the challenges and opportunities in emerging markets, with a focus on Asia.

Inizio

National Institute for Health and Care Excellence NICE logo

Cancer charities criticise NICE’s ‘last-century methodology’

Group of 15 claims many new prostate cancer drugs will now ‘struggle to gain approval’

EISAI

Eisai gets green light for Lenvima in kidney cancer

New drug awarded breakthrough and priority review status by FDA in RCC

- PMLiVE

Publicis appoints Kipp Jarecke-Cheng as global comms chief

He joins the network from US digital design agency FOUR32C

- PMLiVE

Shaking up medical communication

...we’re talking to you

Lucid reach the shortlist for Communiqué 2016 in SIX categories

Lucid Group are celebrating the news that for the first time they have been shortlisted in six different categories at this year’s Communiqué awards.  The categories are:Excellence in Communications of...

Lucid Group Communications Limited

- PMLiVE

Finland’s Faron Pharmaceuticals appoints new medical director

Dr Matti Karvonen brings experience from Roche, Biogen and Novartis

90TEN Willoughby Badger Deepa Patel Anna Reidinger

90TEN boosts PR division with new hires

Appoints Willoughby Badger, Deepa Patel and Anna Reidinger

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links